Sanofi keeps foot on the gas, agree­ing to five-year col­lab­o­ra­tion with MD An­der­son

Just four months af­ter scor­ing its first can­cer drug ap­proval in a decade, Sanofi is stay­ing on the on­col­o­gy of­fen­sive.

The French phar­ma is plan­ning to ac­cel­er­ate the de­vel­op­ment of po­ten­tial treat­ments, part­ner­ing with the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter in a five-year col­lab­o­ra­tion. By com­bin­ing Sanofi’s pipeline with MD An­der­son’s top-notch clin­i­cal tri­al pro­gram in on­col­o­gy, the pair will launch bio­mark­er-dri­ven clin­i­cal stud­ies to bet­ter un­der­stand which drug cock­tails can ef­fec­tive­ly curb can­cer pro­gres­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER